Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||LXH 254 + Ribociclib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LXH 254||LXH254|LXH-254||BRAF Inhibitor 21 CRAF Inhibitor 11||LXH 254 is a RAF inhibitor that selectively inhibits monomeric and dimerized BRAF and CRAF, which may lead to anti-tumor activity in RAF-mutant tumors and better tolerability (AACR Annual Meeting 2019, Abstract LB-114, PMID: 31059256).|
|Ribociclib||Kisqali||LEE011||CDK4/6 Inhibitor 12||Kisqali (ribociclib) is a dual CDK4/6 inhibitor, which may induce cell cycle arrest and reduce proliferation in cancer cells (PMID: 24045179). Kisqali (ribociclib) is FDA-approved in combination with an aromatase inhibitor in women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer, and in combination with Faslodex (fulvestrant) in postmenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02974725||Phase I||LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254||A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma||Active, not recruiting||USA | ITA | FRA | ESP | DEU | BEL||5|